Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expression profiling analysis of the CD5<sup>+</sup> diffuse large B‐cell lymphoma subgroup: Development of a CD5 signature

13 Jul 2006

Abstract excerpt

Diffuse large B-cell lymphoma (DLBCL) accounts for 30% of non-Hodgkin's lymphomas and is known to comprise heterogeneous groups. We previously reported that CD5+ DLBCL is a clinically distinct subgroup of these tumors that is associated with poor prognosis. In our current study, we have used gene expression profiling technology in an attempt to identify new markers and to further characterize the biological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lymphoma Diagnosis and Treatment
Share to Molecular Biology Techniques and Applications
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16856881
DOI: 10.1111/j.1349-7006.2006.00267.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expression profiling analysis of the CD5<sup>+</sup> diffuse large B‐cell lymphoma subgroup: Development of a CD5 signaturePMID 16856881Read ↗

Genome-Wide Array-Based Comparative Genomic Hybridization of Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Multiple Omics Analysis Reveals E2F5 Predict Prognostic Biomarker in Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Differentially expressed tRFs in CD5 positive relapsed & refractory diffuse large B cell lymphoma and the bioinformatic analysis for their potential clinical useSemantic proximity Read ↗

De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.Semantic proximity Read ↗

CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.Semantic proximity Read ↗

Pathway analysis of informative genes from microarray data reveals that metabolism and signal transduction genes distinguish different subtypes of lymphomas.Semantic proximity Read ↗

CD5L is a Potential Hepatocellular Carcinoma Biomarker for Clinical prognostic and immunotherapySemantic proximity Read ↗

Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes.Semantic proximity Read ↗

De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.Semantic proximity Read ↗

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphomaSemantic proximity Read ↗

Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization.Semantic proximity Read ↗

Microarray‐based classification of diffuse large B‐cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.